AR018107A1 - Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo - Google Patents
Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivoInfo
- Publication number
- AR018107A1 AR018107A1 ARP990100728A ARP990100728A AR018107A1 AR 018107 A1 AR018107 A1 AR 018107A1 AR P990100728 A ARP990100728 A AR P990100728A AR P990100728 A ARP990100728 A AR P990100728A AR 018107 A1 AR018107 A1 AR 018107A1
- Authority
- AR
- Argentina
- Prior art keywords
- particle
- organic compound
- solvent
- group
- size
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 11
- 150000002894 organic compounds Chemical class 0.000 abstract 9
- 239000002904 solvent Substances 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 229930182558 Sterol Natural products 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- 239000012736 aqueous medium Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 2
- 238000002844 melting Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- 150000003431 steroids Chemical class 0.000 abstract 2
- 150000003432 sterols Chemical class 0.000 abstract 2
- 235000003702 sterols Nutrition 0.000 abstract 2
- 230000008016 vaporization Effects 0.000 abstract 2
- 238000009834 vaporization Methods 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 229940107161 cholesterol Drugs 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229940011871 estrogen Drugs 0.000 abstract 1
- 239000000262 estrogen Substances 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 239000004005 microsphere Substances 0.000 abstract 1
- -1 pH regulators Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
- 230000000079 pharmacotherapeutic effect Effects 0.000 abstract 1
- 239000006187 pill Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 230000000717 retained effect Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2989—Microcapsule with solid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Un método para efectuar la cristalizacion en estado solido de un compuesto orgánico molecular alotropico en una partícula de tamano y forma definidos, quecomprende: (i) exposicion de dicha partícula a una atmosfera saturada con un solvente para dichocompuesto orgánico; y (ii) recuperacion de dicha partícula, endihco compuesto orgánico en dicha partícula recuperada es de estructura cristalina uniforme, y dicha partícula recuperada ha retenido dicho tamano y forma.Dicha partícula se selecciona del grupo que integran: un solido liofilizado, una pastilla, y un implante. La forma preferida de dicha partícula es la de unamicroesferea de un diámetro de entre aproximadamente 1 y 1.000 micrones. La partícula se puede formar primeramente por fusion-congelacion de dicho compuestoorgánico para dar una microesfera. Dicho solvente se selecciona del grupo que integran: agua, etanol, acetona, ácido acético, tolueno, benceno y dichocompuesto orgánico es un agente farmacoterapéutico que exhibe polimorfismo, el cual puede ser, en esterol o un esteroide. Dicho esterol o esteroide seselecciona del grupo que integran: 17-beta-estradiol, estrogeno, testosterona, progesterona, colesterol, y mezclas de los mismos. La atmosfera se mantien a unatemperaturasuficiente para conseguir la vaporizacion de dicho solvente, pero por debajo del punto de fusion de dicho compuesto orgánico. La atmosfera semantiene a una temperatura suficiente para conseguir la vaporizacion de dicho solvente, pero por debajo delpunto de fusion de dicho compuesto orgánico. Lapartícula recuperada se almacena posteriormente en forma seca o en un medio acuoso, manteniendo dichos tamano y forma durante el almacenamiento en mediosacuosos por lo menos durante alrededor de un mes.Dicha partícula también comprende un aditivo seleccionado del grupo que integran; excipientes farmacéuticos,reguladores de pH, estabilizantes y combinaciones de los mismos y la forma cristalina deseada del compuesto orgánico alotropico es un hidrato.Dicho método esaplicado a una mezcla que contiene al menos un compuesto orgánico molecular alotropico, en donde dicha mezcla ha sido además congelada para dar lugar a una
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/030,388 US6287693B1 (en) | 1998-02-25 | 1998-02-25 | Stable shaped particles of crystalline organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR018107A1 true AR018107A1 (es) | 2001-10-31 |
Family
ID=21853984
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990100728A AR018107A1 (es) | 1998-02-25 | 1999-02-23 | Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo |
| ARP100100845A AR077168A2 (es) | 1998-02-25 | 2010-03-17 | Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida |
| ARP100100844A AR077167A2 (es) | 1998-02-25 | 2010-03-17 | Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100845A AR077168A2 (es) | 1998-02-25 | 2010-03-17 | Particulas estables en almacenamiento de compuestos organicos cristalinos de forma definida |
| ARP100100844A AR077167A2 (es) | 1998-02-25 | 2010-03-17 | Metodo para realizar la cristalizacion en estado solido de particulas conformadas de compuestos organicos alotropicos |
Country Status (34)
| Country | Link |
|---|---|
| US (7) | US6287693B1 (es) |
| EP (4) | EP1056444B1 (es) |
| JP (2) | JP4885357B2 (es) |
| KR (1) | KR100726315B1 (es) |
| CN (2) | CN1146407C (es) |
| AR (3) | AR018107A1 (es) |
| AT (2) | ATE345779T1 (es) |
| AU (1) | AU747779B2 (es) |
| BR (1) | BR9908156A (es) |
| CA (1) | CA2319176C (es) |
| CL (1) | CL2010001333A1 (es) |
| CY (1) | CY1118522T1 (es) |
| CZ (1) | CZ301042B6 (es) |
| DE (2) | DE69934099T2 (es) |
| DK (3) | DK2085075T3 (es) |
| EE (1) | EE05019B1 (es) |
| ES (3) | ES2609284T3 (es) |
| HU (1) | HUP0101271A3 (es) |
| ID (1) | ID26523A (es) |
| IL (2) | IL137970A0 (es) |
| MY (1) | MY138375A (es) |
| NO (1) | NO331804B1 (es) |
| NZ (1) | NZ505987A (es) |
| PE (1) | PE20000393A1 (es) |
| PL (1) | PL196369B1 (es) |
| PT (1) | PT2085075T (es) |
| RU (1) | RU2225708C2 (es) |
| SA (1) | SA99200098B1 (es) |
| TR (1) | TR200002462T2 (es) |
| TW (1) | TWI256308B (es) |
| UA (1) | UA73470C2 (es) |
| UY (1) | UY25404A1 (es) |
| WO (1) | WO1999043304A1 (es) |
| ZA (1) | ZA991058B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6287693B1 (en) | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| CA2485834C (en) | 2002-05-16 | 2007-07-17 | Tibotec Pharmaceuticals Ltd. | Pseudopolymorphic forms of a hiv protease inhibitor |
| US20040028747A1 (en) * | 2002-08-06 | 2004-02-12 | Tucker Christopher J. | Crystalline drug particles prepared using a controlled precipitation process |
| US20040028746A1 (en) * | 2002-08-06 | 2004-02-12 | Sonke Svenson | Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| EP1844765B1 (en) * | 2003-06-13 | 2015-01-21 | Skendi Finance, Ltd. | Slow release estradiol-progesterone formulation |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| CA2532874A1 (en) * | 2003-07-22 | 2005-02-03 | Baxter International Inc. | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof |
| SI1691787T1 (sl) * | 2003-12-04 | 2008-10-31 | Pfizer Prod Inc | Postopek za pripravo farmacevtskih produktov iz več delcev |
| PL1718258T3 (pl) | 2004-02-23 | 2009-08-31 | Euro Celtique Sa | Odporne na nadużywanie transdermalne urządzenie do podawania opioidu |
| RU2008100543A (ru) * | 2005-06-17 | 2009-07-27 | БАСФ Акциенгезельшафт (DE) | Способ получения усилителей эффекта отбеливания |
| WO2009120889A2 (en) * | 2008-03-26 | 2009-10-01 | Alltranz Inc. | Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists |
| EP2272519A4 (en) * | 2008-04-14 | 2011-04-27 | Posi Visionary Solutions Llp | METHOD AND PHARMACEUTICAL COMPOSITION FOR ACHIEVING THE PLASMA PROGESTERONE MIRRORS NECESSARY FOR VARIOUS THERAPEUTIC INDICATIONS |
| FR2939326B1 (fr) * | 2008-12-10 | 2011-04-01 | Univ Joseph Fourier | Procede et dispositif de controle d'une cristallisation. |
| AU2009352681B2 (en) | 2009-09-17 | 2014-11-20 | Upsher-Smith Laboratories, Llc | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
| UY33103A (es) * | 2009-12-15 | 2011-07-29 | Techsphere S A De C V | Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico |
| ES2560955T3 (es) * | 2010-03-19 | 2016-02-23 | Daiichi Sankyo Company, Limited | Cristal de derivado de diamina y procedimiento de producción del mismo |
| KR101314126B1 (ko) | 2011-03-11 | 2013-10-04 | 서울대학교산학협력단 | 다면체 형상의 약물 전달 시스템 |
| US9351924B2 (en) | 2011-03-11 | 2016-05-31 | Snu R&Db Foundation | Drug delivery system including laminated structure |
| EP3936133A1 (en) | 2011-11-23 | 2022-01-12 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| MX366703B (es) | 2013-03-15 | 2019-07-22 | Incyte Holdings Corp | Heterociclos tricíclicos como inhibidores de la proteína bet. |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| EA034972B1 (ru) | 2014-04-23 | 2020-04-13 | Инсайт Корпорейшн | 1h-пирроло[2,3-c]пиридин-7(6h)-оны в качестве ингибиторов белков bet |
| US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| ITUB20153652A1 (it) | 2015-09-16 | 2017-03-16 | Fatro Spa | Microsfere contenenti lattoni macrociclici antielminitici |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CA3020153A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| PT3472157T (pt) | 2016-06-20 | 2023-05-30 | Incyte Corp | Formas sólidas cristalinas de um inibidor bet |
| PL236889B1 (pl) * | 2017-10-03 | 2021-02-22 | Univ Warszawski Medyczny | Nowa forma krystaliczna bezwodnego 17-β-estradiolu, sposób jej otrzymywania oraz kompozycja farmaceutyczna zawierająca nową formę krystaliczną bezwodnego 17-β-estradiolu i jej zastosowanie |
| EP3542786A1 (en) * | 2018-03-21 | 2019-09-25 | ITF Research Pharma, S.L.U. | Progesterone intravaginal devices |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2447362A (en) | 1945-11-01 | 1948-08-17 | Rca Corp | Production of crystals |
| US3800038A (en) * | 1972-04-21 | 1974-03-26 | Biolog Concepts Inc | Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier |
| US4230621A (en) * | 1978-05-01 | 1980-10-28 | E. R. Squibb & Sons, Inc. | Steroid derivatives and their use in radioimmunoassays |
| DE2843963A1 (de) * | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
| IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
| JPS5799562A (en) | 1980-12-12 | 1982-06-21 | Nippon Shinyaku Co Ltd | Preparation of microcrystal |
| DE3049196A1 (de) | 1980-12-24 | 1982-07-29 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von granulaten aus organischen in form einer schmelze vorliegenden stoffen |
| US4447426A (en) * | 1982-01-18 | 1984-05-08 | E. R. Squibb & Sons, Inc. | Steroid monohydrates, formulations containing same and method |
| JPS58143832A (ja) | 1982-02-22 | 1983-08-26 | Yoshiaki Kawashima | 結晶性化学物質の球状化再結晶法 |
| DE3213025C2 (de) | 1982-04-02 | 1997-06-12 | Fischer Karl Ind Gmbh | Verfahren zur Nachkondensation von Polykondensaten |
| GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
| JPH0714625B2 (ja) | 1987-03-30 | 1995-02-22 | 呉羽化学工業株式会社 | 高結晶化ポリアリ−レンチオエ−テル成形物 |
| US4897307A (en) | 1987-08-11 | 1990-01-30 | The Dow Chemical Company | Process for the solvent-induced crystallization of amorphous poly(etheretherketone)-type polymers and the article formed thereby |
| WO1989002904A1 (fr) | 1987-09-28 | 1989-04-06 | Asahi Kasei Kogyo Kabushiki Kaisha | Procede de preparation de polycarbonate aromatique cristallise et polycarbonate aromatique cristallise ainsi obtenu |
| US4919899A (en) | 1988-02-29 | 1990-04-24 | Herrmann Frederick T | Crystal growth apparatus |
| YU120988A (en) * | 1988-06-23 | 1990-06-30 | Lek Tovarna Farmacevtskih | Process for preparing new dispersion pills of cimetidine |
| IT1230566B (it) * | 1988-10-17 | 1991-10-28 | Vectorpharma Int | Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione |
| US5360478A (en) | 1989-10-16 | 1994-11-01 | Phasex Corporation | Gas anti-solvent recrystallization process |
| FR2663223B1 (fr) | 1990-06-14 | 1994-12-02 | Af Aplicaciones Far Lab | Forme galenique parenterale. |
| FR2663224B1 (fr) * | 1990-06-14 | 1995-01-20 | Applicationes Farmaceuticas Sa | Forme galenique parenterale. |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| JPH04305226A (ja) | 1991-01-25 | 1992-10-28 | Senichi Masuda | ガス中窒素酸化物の低減方法 |
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| SE9101090D0 (sv) | 1991-04-11 | 1991-04-11 | Astra Ab | Process for conditioning of water-soluble substances |
| US5391810A (en) | 1991-05-23 | 1995-02-21 | Ajinomoto Co., Inc. | Method of crystallizing α-L-aspartyl-L-phenylalanine methyl ester |
| DE4130173A1 (de) | 1991-09-11 | 1993-03-18 | Bayer Ag | Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters |
| DE4218929C1 (es) | 1992-06-10 | 1993-09-09 | Deutsche Bundesbahn, Vertreten Durch Das Bundesbahn-Zentralamt Minden (Westf.), 4950 Minden, De | |
| US5290913A (en) | 1992-10-08 | 1994-03-01 | Carrier Vibrating Equipment, Inc. | Method and apparatus for the heat treatment of material |
| US5558678A (en) | 1992-11-13 | 1996-09-24 | Karl Fischer Industrieanlagen Gmbh | Process and apparatus for continuous crystallization of plastic granules |
| US5643595A (en) | 1992-11-24 | 1997-07-01 | Alkermes Controlled Therapeutics Inc. Ii | Growth promoters for animals |
| WO1994020116A1 (en) * | 1993-03-10 | 1994-09-15 | University Of Alabama Research Foundation | Artificial primers for glycogen synthesis |
| US5409605A (en) * | 1993-08-05 | 1995-04-25 | Chemical Lime Company | Apparatus and method for treating waste sludge |
| JPH0757558A (ja) * | 1993-08-09 | 1995-03-03 | Showa Electric Wire & Cable Co Ltd | 耐熱絶縁電線 |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| US5849651A (en) * | 1995-06-01 | 1998-12-15 | Kabushiki Kaisha Toshiba | Reversible thermal recording medium |
| JPH0957558A (ja) * | 1995-08-18 | 1997-03-04 | Nabeya Iron & Tool Works Ltd | スライド装置 |
| JPH09227558A (ja) * | 1996-02-28 | 1997-09-02 | Fujisawa Pharmaceut Co Ltd | チアゾール化合物の安定な結晶およびその製造方法 |
| US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
| JP2000143832A (ja) | 1998-11-10 | 2000-05-26 | Toppan Printing Co Ltd | 高剛性を有するフィルムまたはシート |
-
1998
- 1998-02-25 US US09/030,388 patent/US6287693B1/en not_active Expired - Lifetime
-
1999
- 1999-02-10 EP EP99902729A patent/EP1056444B1/en not_active Expired - Lifetime
- 1999-02-10 AT AT99902729T patent/ATE345779T1/de active
- 1999-02-10 ID IDW20001723A patent/ID26523A/id unknown
- 1999-02-10 EP EP09156268.6A patent/EP2085075B1/en not_active Expired - Lifetime
- 1999-02-10 ES ES09156268.6T patent/ES2609284T3/es not_active Expired - Lifetime
- 1999-02-10 BR BR9908156-3A patent/BR9908156A/pt not_active Application Discontinuation
- 1999-02-10 NZ NZ505987A patent/NZ505987A/en not_active IP Right Cessation
- 1999-02-10 HU HU0101271A patent/HUP0101271A3/hu unknown
- 1999-02-10 KR KR1020007009352A patent/KR100726315B1/ko not_active Expired - Fee Related
- 1999-02-10 ES ES99902729T patent/ES2275334T3/es not_active Expired - Lifetime
- 1999-02-10 DK DK09156268.6T patent/DK2085075T3/en active
- 1999-02-10 AU AU22936/99A patent/AU747779B2/en not_active Expired
- 1999-02-10 CZ CZ20003047A patent/CZ301042B6/cs not_active IP Right Cessation
- 1999-02-10 DK DK06022834T patent/DK1772141T3/da active
- 1999-02-10 CN CNB998032794A patent/CN1146407C/zh not_active Expired - Fee Related
- 1999-02-10 RU RU2000124327/15A patent/RU2225708C2/ru not_active IP Right Cessation
- 1999-02-10 ZA ZA9901058A patent/ZA991058B/xx unknown
- 1999-02-10 JP JP2000533103A patent/JP4885357B2/ja not_active Expired - Fee Related
- 1999-02-10 PT PT91562686T patent/PT2085075T/pt unknown
- 1999-02-10 CN CNB2004100076469A patent/CN100528140C/zh not_active Expired - Fee Related
- 1999-02-10 DE DE69934099T patent/DE69934099T2/de not_active Expired - Lifetime
- 1999-02-10 TR TR2000/02462T patent/TR200002462T2/xx unknown
- 1999-02-10 ES ES06022834T patent/ES2324366T3/es not_active Expired - Lifetime
- 1999-02-10 EE EEP200000492A patent/EE05019B1/xx unknown
- 1999-02-10 PL PL343170A patent/PL196369B1/pl unknown
- 1999-02-10 EP EP10183811A patent/EP2319497B1/en not_active Expired - Lifetime
- 1999-02-10 IL IL13797099A patent/IL137970A0/xx active IP Right Grant
- 1999-02-10 DK DK99902729T patent/DK1056444T3/da active
- 1999-02-10 CA CA002319176A patent/CA2319176C/en not_active Expired - Fee Related
- 1999-02-10 AT AT06022834T patent/ATE427102T1/de active
- 1999-02-10 EP EP06022834A patent/EP1772141B1/en not_active Expired - Lifetime
- 1999-02-10 WO PCT/IB1999/000233 patent/WO1999043304A1/en not_active Ceased
- 1999-02-10 DE DE69940684T patent/DE69940684D1/de not_active Expired - Lifetime
- 1999-02-12 MY MYPI99000491A patent/MY138375A/en unknown
- 1999-02-17 PE PE1999000141A patent/PE20000393A1/es not_active IP Right Cessation
- 1999-02-23 AR ARP990100728A patent/AR018107A1/es not_active Application Discontinuation
- 1999-02-24 UY UY25404A patent/UY25404A1/es not_active Application Discontinuation
- 1999-03-12 TW TW088103853A patent/TWI256308B/zh not_active IP Right Cessation
- 1999-05-05 SA SA99200098A patent/SA99200098B1/ar unknown
- 1999-10-02 UA UA2000095446A patent/UA73470C2/uk unknown
-
2000
- 2000-07-12 US US09/615,061 patent/US6537580B1/en not_active Expired - Lifetime
- 2000-08-20 IL IL137970A patent/IL137970A/en not_active IP Right Cessation
- 2000-08-24 NO NO20004241A patent/NO331804B1/no not_active IP Right Cessation
-
2001
- 2001-05-23 US US09/862,723 patent/US6528094B1/en not_active Expired - Lifetime
-
2002
- 2002-01-15 US US10/045,148 patent/US6638536B2/en not_active Expired - Lifetime
- 2002-05-29 US US10/156,079 patent/US6663895B2/en not_active Expired - Lifetime
-
2003
- 2003-02-26 US US10/372,897 patent/US7427413B2/en not_active Expired - Fee Related
- 2003-02-26 US US10/373,088 patent/US6737081B2/en not_active Expired - Lifetime
-
2010
- 2010-03-17 AR ARP100100845A patent/AR077168A2/es not_active Application Discontinuation
- 2010-03-17 AR ARP100100844A patent/AR077167A2/es not_active Application Discontinuation
- 2010-12-02 CL CL2010001333A patent/CL2010001333A1/es unknown
-
2011
- 2011-07-22 JP JP2011161017A patent/JP2011241220A/ja not_active Withdrawn
-
2016
- 2016-12-28 CY CY20161101356T patent/CY1118522T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR018107A1 (es) | Pluralidad de particulas estables durante el almacenamiento de un tamano y forma definitivo | |
| JPS59137790A (ja) | 潜熱貯蔵供給方法および装置 | |
| CO5560540A2 (es) | Composicion cristalina que contiene escitalopram | |
| RU2000124327A (ru) | Стабильные частицы определенной формы кристаллических органических соединений | |
| BR0210867A (pt) | Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio | |
| ES8707424A1 (es) | Un procedimiento para encapsular un compuesto organico cuya solubilidad es mayor en un primer disolvente que en un se- gundo disolvente | |
| KR830007671A (ko) | 결정성 1,1-디옥소페니실라노일옥시메틸 6-(D-α-아미노-α-페닐아세트아미도)페니실라네이트 토실레이트 수화물의 제조방법 | |
| AR038648A1 (es) | Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina | |
| WO1998016205A3 (en) | Stable glassy state powder formulations | |
| PE20010983A1 (es) | Forma de dosificacion de farmaco en capas impulsada por hidrogel | |
| US3636010A (en) | Esters of steroid-17-carboxylic acids | |
| Khan et al. | Preparation, characterization, and evaluation of physicochemical properties of different crystalline forms of ibuprofen | |
| Davey et al. | Purification of molecular mixtures below the eutectic by emulsion crystallization | |
| JPS5843999A (ja) | Ｄ−ホモステロイドの製造方法 | |
| CN101511441A (zh) | 净化离子液体的方法 | |
| KR950701898A (ko) | 부분적으로 브롬화된 디페닐 에테르 혼합물의 분리(isolation of partially brominated diphenyl ether mixtures) | |
| ES2131014A1 (es) | Metodo para preparar sales mixtas de glucosamina. | |
| BR9601302A (pt) | Processo para fabricação de um derivado poliglucosamina covalentement ligado derivado poliglucosamina compostos e composição | |
| Wright et al. | Biocytin, a naturally-occurring complex of biotin | |
| JPS5824599A (ja) | 硫酸塩セルロ−ス方法からの粗製石けん中の不けん化物から単離したβ−シトステロ−ルの精製方法 | |
| PE27799A1 (es) | Formulaciones y formas polimorficas de desferrioxamina y su preparacion | |
| Arias et al. | Thermal Study of Different Omeprazole-Γ-CD CO-Ground Systems | |
| PT87907B (pt) | Processo de preparacao do acido 3-(3-piridil)-1h-3h-pirrolo{1,2-c}-7-tiazolocarboxilico dextrogiro | |
| JPS5822897A (ja) | 蓄熱材 | |
| TH42554A3 (th) | อนุภาคแบบเป็นรูปทรงที่เสถียรของสารประกอบอินทรีย์ที่เป็นผลึก |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |